A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.
Cancer medicine（2023）
摘要
TACE combined with lenvatinib and camrelizumab is a well-tolerated modality treatment with promising efficacy for advanced HCC with PVTT.
更多查看译文
关键词
camrelizumab, hepatocellular carcinoma, lenvatinib, portal vein tumor thrombus, transarterial chemoembolization
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要